Brooke R. Daniel, M.D. - Tennessee Oncology

Dr. Brooke Daniel, M.D.

Claim this profile

Tennessee Oncology - Chattanooga Oncology & Hematology Associates

Studies Breast Cancer
Studies Pancreatic Cancer
9 reported clinical trials
16 drugs studied

Area of expertise

1

Breast Cancer

Brooke Daniel, M.D. has run 9 trials for Breast Cancer. Some of their research focus areas include:

Stage IV
Stage III
HER2 negative
2

Pancreatic Cancer

Brooke Daniel, M.D. has run 3 trials for Pancreatic Cancer. Some of their research focus areas include:

Stage IV
Stage III
HER2 negative

Affiliated Hospitals

Image of trial facility.

Chattanooga Oncology And Hematology Associates/Tennessee Oncology-Memorial Plaza

Image of trial facility.

Tennessee Oncology - Chattanooga

Clinical Trials Brooke Daniel, M.D. is currently running

Image of trial facility.

Lasofoxifene and Abemaciclib vs Fulvestrant and Abemaciclib

for Breast Cancer

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.

Recruiting

2 awards

Phase 3

12 criteria

Image of trial facility.

Sacituzumab Govitecan + Pembrolizumab

for Triple Negative Breast Cancer

This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: * Sacituzumab govitecan (Trodelvy™;IMMU-132) * Pembrolizumab (Keytruda®; MK-3475)

Recruiting

1 award

Phase 2

15 criteria

More about Brooke Daniel, M.D.

Clinical Trial Related

2 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Brooke Daniel, M.D. has experience with

  • Abemaciclib
  • Fulvestrant
  • ARX788
  • Tucatinib
  • Trastuzumab Deruxtecan
  • Carboplatin

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Brooke Daniel, M.D. specialize in?

Is Brooke Daniel, M.D. currently recruiting for clinical trials?

Are there any treatments that Brooke Daniel, M.D. has studied deeply?

What is the best way to schedule an appointment with Brooke Daniel, M.D.?

What is the office address of Brooke Daniel, M.D.?

Is there any support for travel costs?